FDA Orders Juul Products to Be Removed from Retailers

Jul.01.2022
FDA Orders Juul Products to Be Removed from Retailers
FDA tried to order retailers to remove Juul products but a federal appeals court suspended the order, citing contrasting arguments.

If the U.S. Food and Drug Administration (FDA) has its way, one of the largest electronic cigarette retailers in the country may be forced out of business. Last Thursday, the FDA began sending letters to retailers ordering them to remove all Juul products from their shelves. The following day, a federal appeals court temporarily suspended the FDA's order, allowing Juul to continue selling its products while the court hears arguments from both sides.

 

The FDA is alleging that Juul has not provided "sufficient evidence regarding the toxicological characteristics of their products to demonstrate that their marketing is appropriate for protecting public health." In response, Juul released a statement calling the FDA's ban "arbitrary and capricious.

 

Is Juuling on the way out?

 

This week, health reporter for Time, Jamie Ducharme argued that the ban on Juul may not be the public health victory that people have imagined, and pointed out that "adult smokers also use Juul for smoking cessation - last week's decision was not a victory for them.

 

Tim Andrews from the US Tax Reform Organization also wrote in the Washington Post that taking Juul products off the market "will cut off a proven method that helps millions of smokers quit, leading to more smoking and more deaths." As evidence, Andrews cited comments "consistently finding e-cigarettes two to six times more effective than other cessation devices" and a study by Georgetown University Medical Center, which estimated that e-cigarettes could save the lives of up to 6.6 million Americans who would live at least 10 years longer.

 

Jonathan Foulds, a professor of public health sciences at Pennsylvania State University, agrees with this sentiment, stating on Twitter that "banning smoking from these life-saving exits because of 'potentially harmful chemicals' that may exude from some pods is a bit like locking the fire escape door because the steps might be slippery.

 

What's worse, Zule or cigars?

 

In his article for the Washington Post, Tim Andrews cited a "meta-analysis" of scientific research on e-cigarettes, commissioned by the UK government and "replicated by external medical institutions," which concluded that e-cigarettes are "95% safer than combustible tobacco." Bloomberg reporters Fiona Rutherford and Robert Langreth acknowledged that "some evidence suggests that e-cigarettes are a safer option than smoking," but claim that "there is not enough long-term data to draw a definitive conclusion." It is worth noting that Michael Bloomberg is a major funder of the campaign to ban flavored e-cigarette products.

 

From April 2019 to February 2020, the US experienced an outbreak of lung injuries related to the use of electronic cigarettes or vaping products, known as EVALI, resulting in 2,807 hospitalizations and 68 deaths. Of note, 82% of hospitalized patients reported using marijuana while only 14% reported nicotine use alone. The Centers for Disease Control and Prevention also found that many of the deaths or hospitalizations were linked to the use of unregulated black-market THC products in their vaping devices. In comparison, smoking is estimated to cause 480,000 deaths per year in the US.

 

However, electronic cigarettes may not be the healthy alternative that some supporters claim. The Johns Hopkins School of Medicine notes that electronic cigarettes have not been approved by the Food and Drug Administration as a smoking cessation device, and "recent research has found that the majority of people who intended to use electronic cigarettes to quit nicotine habit ended up continuing to use both traditional cigarettes and e-cigarettes.

 

Just think about the children!

 

In 2018, 30% of American high school students "reported having tried nicotine at least once in the past year," according to a cover story by Jamie Ducharme in TIME magazine in 2019. This is the largest increase in substance use in at least 44 years. The 2018 report by the National Academy of Sciences also showed that children who use e-cigarettes are more likely to try traditional cigarettes. Although the FDA's decision did not specifically address the relationship between Juul and youth e-cigarette use, as reported by the New York Times, "public health experts and legislators continue to express concern about the addition of nicotine to some e-cigarettes that remain on the market, including brands like PuffBar that offer fruit flavors that are attractive to young people.

 

However, the theory still remains debatable. Writing for a conservative independent women's forum, Lindsey Stroud argues that Juul does not encourage children to smoke. According to a public opinion survey, she wrote, "From 2019 to 2021, the usage of Juul products among 12th-grade students decreased by 46.9% in the past 30 days. Additionally, in 10th-grade students, the number of people using JUUL decreased by 75.3% during that time." The editorial board of The New York Daily News agreed, writing that Juul "has largely lost favor with teenage consumers" in recent years. However, all of this may just be a passing trend, like water vapor evaporating in the wind.

 

Source: The Week

 

This article contains excerpts or reprints of third-party information. The copyright of the reproduced information belongs to the original media and author.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's government unveiled its first Tobacco Harm Management Basic Plan for 2027–2031 on October 29, 2026, proposing broader testing of vaping and heated tobacco products while excluding nicotine analogs such as 6-methyl nicotine. Synthetic nicotine came under tobacco regulation on April 24, and a June investigation found 6-methyl nicotine in 12 liquid inhalation products marketed as nicotine-free. Customs data released in September showed that imports of nicotine analog solutions fell 83.3%, from 12 metric tons in January–April to 2 metric tons in May–August. By September 20, imports had reached approximately 15 metric tons for the year, with 99.99% originating from China. Customs authorities have tightened pre-clearance testing and supply-chain documentation requirements, while the MFDS expects to complete its assessment of nicotine analog hazards by the end of 2026.
Regulations
Nov.04
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22